Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 150 av 198 resultater
Tid
Selskap
Tittel
Sektor
Kategori
07 Mar 2023
22:30 CET
DBV TECHNOLOGIES
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
20103010 Biotechnology
Other subject
07 Mar 2023
22:30 CET
DBV TECHNOLOGIES
DBV Technologies annonce le screening du premier patient de l'essai clinique de phase 3 VITESSE chez des enfants de 4 à 7 ans allergiques à l'arachide.
20103010 Biotechnology
Other subject
02 Mar 2023
23:30 CET
DBV TECHNOLOGIES
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
20103010 Biotechnology
Other subject
02 Mar 2023
23:30 CET
DBV TECHNOLOGIES
DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2022
20103010 Biotechnology
Other subject
02 Mar 2023
22:30 CET
DBV TECHNOLOGIES
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
20103010 Biotechnology
Other subject
02 Mar 2023
22:30 CET
DBV TECHNOLOGIES
DBV technologies annonce ses résultats financiers pour l’exercice 2022 et fait le point sur l’évolution récentes des activités
20103010 Biotechnology
Other subject
27 Feb 2023
07:30 CET
DBV TECHNOLOGIES
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
20103010 Biotechnology
Other subject
27 Feb 2023
07:30 CET
DBV TECHNOLOGIES
DBV Technologies publiera ses résultats financiers pour l’année 2022 et fera le point sur ses activités le 2 mars 2023.
20103010 Biotechnology
Other subject
21 Feb 2023
22:30 CET
DBV TECHNOLOGIES
DBV Technologies participera au prochain congrès de l’AAAAI 2023
20103010 Biotechnology
Other subject
21 Feb 2023
22:30 CET
DBV TECHNOLOGIES
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
20103010 Biotechnology
Other subject
10 Feb 2023
22:30 CET
DBV TECHNOLOGIES
DBV Technologies invitée à participer à une prochaine Conférence Investisseur
20103010 Biotechnology
Other subject
10 Feb 2023
22:30 CET
DBV TECHNOLOGIES
DBV Technologies to Participate in Upcoming Investor Conference
20103010 Biotechnology
Other subject
23 Jan 2023
22:30 CET
DBV TECHNOLOGIES
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
-
Other subject
23 Jan 2023
22:30 CET
DBV TECHNOLOGIES
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
-
Other subject
04 Jan 2023
22:30 CET
DBV TECHNOLOGIES
Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022
20103010 Biotechnology
Other subject
04 Jan 2023
22:30 CET
DBV TECHNOLOGIES
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 décembre 2022
20103010 Biotechnology
Other subject
23 Dec 2022
07:30 CET
DBV TECHNOLOGIES
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
20103010 Biotechnology
Other subject
23 Dec 2022
07:30 CET
DBV TECHNOLOGIES
DBV Technologies annonce la levée de la suspension clinique partielle par la FDA de l'étude clinique pivot de phase 3 VITESSE
20103010 Biotechnology
Other subject
08 Dec 2022
22:30 CET
DBV TECHNOLOGIES
Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022
20103010 Biotechnology
Other subject
08 Dec 2022
22:30 CET
DBV TECHNOLOGIES
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 Novembre 2022
20103010 Biotechnology
Other subject
22 Nov 2022
22:30 CET
DBV TECHNOLOGIES
DBV Technologies to Participate in Upcoming Investor Conference
20103010 Biotechnology
Other subject
22 Nov 2022
22:30 CET
DBV TECHNOLOGIES
DBV Technologies invitée à participer à une prochaine Conférence Investisseur
20103010 Biotechnology
Other subject
09 Nov 2022
07:30 CET
DBV TECHNOLOGIES
DBV Technologies to Highlight New Clinical Data at ACAAI 2022
20103010 Biotechnology
Other subject
09 Nov 2022
07:30 CET
DBV TECHNOLOGIES
DBV Technologies présentera de nouvelles données cliniques lors de l’ACAAI 2022
20103010 Biotechnology
Other subject
03 Nov 2022
21:30 CET
DBV TECHNOLOGIES
DBV Technologies publie ses résultats financiers du troisième trimestre 2022 et fait le point sur ses activités
20103010 Biotechnology
Other subject
03 Nov 2022
21:30 CET
DBV TECHNOLOGIES
DBV Technologies Reports Third Quarter Financial Results and Business Update
20103010 Biotechnology
Other subject
31 Oct 2022
21:30 CET
DBV TECHNOLOGIES
DBV Technologies présente ses résultats financiers du troisième trimestre 2022 et fait le point sur ses activités
20103010 Biotechnology
Other subject
31 Oct 2022
21:30 CET
DBV TECHNOLOGIES
DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update
20103010 Biotechnology
Other subject
20 Oct 2022
22:30 CEST
DBV TECHNOLOGIES
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2022
20103010 Biotechnology
Other subject
20 Oct 2022
22:30 CEST
DBV TECHNOLOGIES
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022
20103010 Biotechnology
Other subject
03 Oct 2022
22:30 CEST
DBV TECHNOLOGIES
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
20103010 Biotechnology
Other subject
03 Oct 2022
22:30 CEST
DBV TECHNOLOGIES
DBV Technologies annonce la nomination du nouveau Président de son Comité d’Audit et de Danièle Guyot-Caparros au Conseil d’Administration
20103010 Biotechnology
Other subject
21 Sep 2022
23:45 CEST
DBV TECHNOLOGIES
DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial
20103010 Biotechnology
Other subject
21 Sep 2022
23:45 CEST
DBV TECHNOLOGIES
DBV Technologies fait le point sur l’étude clinique de phase 3 VITESSE
20103010 Biotechnology
Other subject
07 Sep 2022
22:30 CEST
DBV TECHNOLOGIES
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years
20103010 Biotechnology
Other subject
07 Sep 2022
22:30 CEST
DBV TECHNOLOGIES
DBV Technologies annonce le lancement de l’étude de phase 3 (VITESSE) portant sur le patch Viaskin Peanut modifié chez les enfants allergiques à l’arachide âgés de 4 à 7 ans
20103010 Biotechnology
Other subject
02 Sep 2022
22:30 CEST
DBV TECHNOLOGIES
DBV Technologies to Present at Upcoming Investor Conferences
20103010 Biotechnology
Other subject
02 Sep 2022
22:30 CEST
DBV TECHNOLOGIES
DBV Technologies invité à présenter lors des prochaines conférences investisseurs
20103010 Biotechnology
Other subject
01 Aug 2022
22:30 CEST
DBV TECHNOLOGIES
DBV Technologies Reports Second Quarter 2022 Financial Results
20103010 Biotechnology
Other subject
01 Aug 2022
22:30 CEST
DBV TECHNOLOGIES
DBV Technologies publie ses résultats financiers du deuxième trimestre 2022
20103010 Biotechnology
Other subject
27 Jul 2022
22:30 CEST
DBV TECHNOLOGIES
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF
20103010 Biotechnology
Other subject
27 Jul 2022
22:30 CEST
DBV TECHNOLOGIES
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
20103010 Biotechnology
Other subject
20 Jul 2022
22:30 CEST
DBV TECHNOLOGIES
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 juin 2022
20103010 Biotechnology
Other subject
20 Jul 2022
22:30 CEST
DBV TECHNOLOGIES
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022
20103010 Biotechnology
Other subject
29 Jun 2022
00:15 CEST
DBV TECHNOLOGIES
DBV Technologies participera au prochain congrès EAACI 2022
20103010 Biotechnology
Other subject
29 Jun 2022
00:15 CEST
DBV TECHNOLOGIES
DBV Technologies to Participate in Upcoming EAACI 2022 Congress
20103010 Biotechnology
Other subject
16 Jun 2022
07:30 CEST
DBV TECHNOLOGIES
DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York
20103010 Biotechnology
Other subject
16 Jun 2022
07:30 CEST
DBV TECHNOLOGIES
DBV Technologies invitée à présenter à la conférence JMP Securities Life Sciences à New York
20103010 Biotechnology
Other subject
09 Jun 2022
08:55 CEST
DBV TECHNOLOGIES
DBV Technologies Announces Private Placement Financing of $194 Million
20103010 Biotechnology
Other subject
09 Jun 2022
08:55 CEST
DBV TECHNOLOGIES
DBV Technologies annonce un financement par placement privé d'un montant de 194 millions de dollars américains
20103010 Biotechnology
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva